查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1941516

抗真菌药物市场规模、份额和趋势分析报告：按药物类别、适应症、剂型、分销管道、地区和细分市场预测（2026-2033 年）

Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Polyenes, Allylamines, Echinocandins), By Indication, By Dosage Form, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

抗真菌药物市场概况

2025年全球抗真菌药物市场规模估计为169.3亿美元，预计2033年将达到233.9亿美元。

预计从 2026 年到 2033 年，该市场将以 4.19% 的复合年增长率成长。推动市场成长的因素包括真菌感染疾病的增加趋势，尤其是在免疫力缺乏的患者中，以及对有效治疗方法日益增长的需求。

此外，抗真菌药物研发的进步和公众意识的提高也促进了市场扩张。由于已开发国家和开发中国家真菌感染疾病的发生率不断上升，全球市场正经历显着增长。院内感染（HAI），尤其是念珠菌血症，是推动抗真菌治疗需求成长的主要因素。根据世界卫生组织（WHO）2024年的报告，真菌感染疾病是全球大量医院获得性感染的病因，而免疫力缺乏患者数量的增加，包括接受癌症治疗、器官移植和免疫抑制治疗的患者，加剧了这一问题。

这些感染疾病在全球日益加重，尤其是在医疗基础设施不断完善的地区，导致对抗真菌疗法的需求持续增长。此外，多重抗药性病原体（例如耳念珠菌）的传播也引发了人们的担忧，并促使人们努力研发新型、更有效的抗真菌药物。耳Auris已被美国疾病管制与预防中心（CDC）列为2024年全球紧急健康威胁。同时，诸如足癣、甲癣和阴道念珠菌症等浅表真菌感染疾病的持续流行也使得全球对处方药和非处方药（OTC）抗真菌治疗的需求保持稳定。

抗真菌药物研发的技术进步是塑造市场格局的关键因素。新型抗真菌药物，例如2023年核准的瑞札芬净，可望拓展侵袭性真菌感染疾病的治疗选择。这种全身性抗真菌药物每週只需给药一次，因其临床和经济优势，尤其是在门诊治疗方面，而备受关注。此外，新的治疗层级和药物也不断研发中。例如，新型Gwt1抑制剂福斯马诺吉匹（fosmanogepix）和针对抗药性曲菌的奥洛芬（olorofim）等，正在应对重要的治疗挑战，尤其是在免疫力缺乏患者中。这些创新，以及分子诊断等诊断技术的持续进步，正在改善病原体的识别，并实现更具针对性的治疗。因此，随着新治疗方法的引入和临床应用，市场持续扩张，为患者和医疗系统带来更高的疗效和便利性。

儘管取得了这些进展，但由于抗真菌药物抗药性和治疗成本不断上涨，市场仍面临严峻的挑战。对常用抗真菌药物（如Azole和Echinocandins）的抗药性日益普遍。美国疾病管制与预防中心 (CDC) 2024 年的报告指出，耳Auris感染疾病急剧增加，在某些地区，Fluconazole的抗药性率超过 90%，使其成为最难治疗的病原体之一。这种广泛的抗药性正在削弱现有疗法的有效性，并催生对价格更高的新型抗真菌药物的需求。新型疗法（如瑞札芬净）的高成本及其在许多地区（尤其是中低收入国家）的可及性有限，是市场成长的重要障碍。此外，在资源匮乏的环境中，诊断延迟和获得先进抗真菌治疗的机会有限，加剧了真菌感染疾病带来的公共卫生负担。虽然药物研发的进步带来了希望，但确保这些治疗方法的可及性和可负担性，尤其是在服务不足的市场，对于充分发挥市场的潜力至关重要。

目录

第一章调查方法和范围

第二章执行摘要

第三章抗真菌药物市场变数、趋势和范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章抗真菌药物市场：按药物类别分類的业务分析

  • 按药物类别分類的市场份额（2025 年和 2033 年）
  • 按药物类别分類的市场规模、预测和趋势分析（2021-2033 年）
  • Azole
  • Echinocandins
  • Polyenes
  • Allylamines
  • 其他的

第五章抗真菌药物市场：按适应症分類的业务分析

  • 按适应症分類的市场份额（2025 年和 2033 年）
  • 按适应症分類的市场规模、预测和趋势分析（2021-2033 年）
  • 皮肤丝状菌症
  • 曲菌症
  • 念珠菌症
  • 其他的

第六章抗真菌药物市场：按剂型分類的业务分析

  • 按剂型分類的市场份额（2025 年和 2033 年）
  • 按剂型分類的市场规模、预测与趋势分析（2021-2033 年）
  • 口服药物
  • 软膏
  • 粉末
  • 其他的

第七章抗真菌药物市场：按分销管道分類的业务分析

  • 按分销管道分類的市场份额（2025 年和 2033 年）
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医院药房
  • 零售药房
  • 其他药房

第八章抗真菌药物市场：区域估算与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Bausch Health Companies Inc.
    • Pfizer, Inc.
    • Bayer AG
    • Sandoz
    • Merck &Co., Inc.
    • GSK plc.
    • Kenvue
    • GLENMARK
    • Janssen Pharmaceuticals
    • Astellas Pharma, Inc.
Product Code: GVR-1-68038-293-8

Antifungal Drugs Market Summary

The global antifungal drugs market size was estimated at USD 16.93 billion in 2025 and is projected to reach USD 23.39 billion by 2033, growing at a CAGR of 4.19% from 2026 to 2033. The market is driven by the increasing prevalence of fungal infections, particularly among immunocompromised patients, and the rising demand for effective treatment options.

In addition, advancements in antifungal drug development and growing awareness contribute to market expansion. The global market is witnessing substantial growth, driven by the increasing incidence of fungal infections across both developed and developing regions. Hospital-associated infections (HAIs), particularly candidemia, are a major contributor to the rising demand for antifungal treatments. According to the World Health Organization (WHO) in 2024, fungal infections are responsible for a significant number of hospital-related infections worldwide, exacerbated by the increasing number of immunocompromised patients, such as those undergoing cancer treatments, organ transplants, or immunosuppressive therapies.

The growing global burden of such infections, especially in regions with expanding healthcare infrastructure, contributes to sustained demand for antifungal therapies. Furthermore, the spread of multidrug-resistant pathogens like Candida auris, identified as an urgent global health threat by the CDC in 2024, has heightened concerns and prompted efforts to develop new and more effective antifungal drugs. The persistent prevalence of superficial fungal infections, such as athlete's foot, onychomycosis, and vaginal candidiasis, also ensures a steady demand for both prescription and over-the-counter (OTC) antifungal treatments globally.

Technological advancements in antifungal drug development are a key factor shaping the market landscape. The approval of novel antifungal agents, such as rezafungin in 2023, is expected to expand the treatment options available for invasive fungal infections. This systemic antifungal, which allows for once-weekly dosing, has gained attention for its clinical and economic advantages, particularly in outpatient settings. In addition, the development of new therapeutic classes and agents, such as fosmanogepix, a novel Gwt1 inhibitor, and olorofim, an orotomide targeting resistant Aspergillus species, is addressing critical gaps in treatment, particularly for immunocompromised populations. These innovations, alongside the ongoing advancements in diagnostic technologies like molecular diagnostics, are improving pathogen identification and enabling more targeted treatments. As a result, the market is expanding as new therapies are introduced and integrated into clinical practice, offering greater efficacy and convenience for patients and healthcare systems alike.

Despite these advancements, the market faces significant challenges, primarily stemming from antifungal resistance and the high costs of treatment. Resistance to commonly used antifungal agents, such as azoles and echinocandins, is becoming increasingly prevalent. The CDC's 2024 report highlights the rapid rise of Candida auris infections, with resistance rates to fluconazole exceeding 90% in some regions, making it one of the most difficult pathogens to treat. This growing resistance undermines the effectiveness of established treatments and creates a demand for newer, more expensive antifungal agents. The high cost of novel therapies, such as rezafungin, and their limited accessibility in many regions, particularly in low- and middle-income countries, presents a significant barrier to market growth. Furthermore, diagnostic delays and limited access to advanced antifungal treatments in resource-constrained settings exacerbate the public health burden of fungal infections. While advancements in drug development offer hope, the ability to make these therapies accessible and affordable, especially in underserved markets, will be crucial for realizing the full market potential.

Global Antifungal Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antifungal drugs market report based on drug class, indication, dosage form, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Others
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Others
  • Dosage Form Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral Drugs
  • Ointments
  • Powders
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Dosage Form
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Antifungal Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Antifungal Drugs Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2025 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
  • 4.4. Azoles
    • 4.4.1. Azoles Market, 2021 - 2033 (USD Billion)
  • 4.5. Echinocandins
    • 4.5.1. Echinocandins Market, 2021 - 2033 (USD Billion)
  • 4.6. Polyenes
    • 4.6.1. Polyenes Market, 2021 - 2033 (USD Billion)
  • 4.7. Allylamines
    • 4.7.1. Allylamines Market, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Other Drug Class Market, 2021 - 2033 (USD Billion)

Chapter 5. Antifungal Drugs Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
  • 5.4. Dermatophytosis
    • 5.4.1. Dermatophytosis Market, 2021 - 2033 (USD Billion)
  • 5.5. Aspergillosis
    • 5.5.1. Aspergillosis Market, 2021 - 2033 (USD Billion)
  • 5.6. Candidiasis
    • 5.6.1. Candidiasis Market, 2021 - 2033 (USD Billion)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Antifungal Drugs Market: Dosage Form Business Analysis

  • 6.1. Dosage Form Market Share, 2025 & 2033
  • 6.2. Dosage Form Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2021 to 2033 (USD Billion)
  • 6.4. Oral Drugs
    • 6.4.1. Oral Drugs Market, 2021 - 2033 (USD Billion)
  • 6.5. Ointments
    • 6.5.1. Ointments Market, 2021 - 2033 (USD Billion)
  • 6.6. Powders
    • 6.6.1. Powders Market, 2021 - 2033 (USD Billion)
  • 6.7. Others
    • 6.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. Antifungal Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.6. Other Pharmacies
    • 7.6.1. Other Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 8. Antifungal Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Antifungal Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Bausch Health Companies Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Pfizer, Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Bayer AG
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Sandoz
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Merck & Co., Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. GSK plc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Kenvue
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. GLENMARK
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Janssen Pharmaceuticals
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Astellas Pharma, Inc.
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Antifungal drugs market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 5 Global antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 6 Global antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 7 Global antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 8 North America antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 9 North America antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 10 North America antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 11 North America antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 12 North America antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 13 US antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 14 US antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 15 US antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 16 US antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Canada antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 18 Canada antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 19 Canada antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 20 Canada antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 21 Mexico antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 22 Mexico antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 23 Mexico antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 24 Mexico antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 25 Europe antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 26 Europe antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 27 Europe antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 28 Europe antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 29 Europe antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 UK antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 31 UK antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 32 UK antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 33 UK antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 34 Germany antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 35 Germany antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 36 Germany antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 37 Germany antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 38 France antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 39 France antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 40 France antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 41 France antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Italy antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 43 Italy antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 44 Italy antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 45 Italy antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 46 Spain antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 47 Spain antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 48 Spain antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 49 Spain antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 50 Norway antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 51 Norway antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 52 Norway antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 53 Norway antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 54 Denmark antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 55 Denmark antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 56 Denmark antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 57 Denmark antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 Sweden antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 59 Sweden antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 60 Sweden antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 61 Sweden antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 62 Asia Pacific antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 63 Asia Pacific antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 64 Asia Pacific antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 65 Asia Pacific antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 66 Asia Pacific antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Japan antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 68 Japan antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 69 Japan antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 70 Japan antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 71 China antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 72 China antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 73 China antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 74 China antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 75 India antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 76 India antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 77 India antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 78 India antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 79 Australia antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 80 Australia antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 81 Australia antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 82 Australia antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 83 South Korea antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 84 South Korea antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 85 South Korea antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 86 South Korea antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Thailand antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 88 Thailand antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 89 Thailand antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 90 Thailand antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 91 Latin America antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 92 Latin America antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 93 Latin America antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 94 Latin America antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 95 Latin America antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 96 Brazil antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 97 Brazil antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 98 Brazil antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 99 Brazil antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 100 Argentina antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 101 Argentina antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 102 Argentina antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 103 Argentina antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 104 Middle East & Africa antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 105 Middle East & Africa antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 106 Middle East & Africa antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 107 Middle East & Africa antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 108 Middle East & Africa antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 109 South Africa antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 110 South Africa antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 111 South Africa antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 112 South Africa antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 113 Saudi Arabia antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 114 Saudi Arabia antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 115 Saudi Arabia antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 116 Saudi Arabia antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 117 UAE antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 118 UAE antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 119 UAE antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 120 UAE antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 121 Kuwait antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 122 Kuwait antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 123 Kuwait antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 124 Kuwait antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Antifungal drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Competitive landscape
  • Fig. 11 Antifungal drugs market dynamics
  • Fig. 12 Antifungal drugs market: Porter's five forces analysis
  • Fig. 13 Antifungal drugs market: PESTLE analysis
  • Fig. 14 Drug Class market, 2021 - 2033 (USD Billion)
  • Fig. 15 Azoles market, 2021 - 2033 (USD Billion)
  • Fig. 16 Echinocandins market, 2021 - 2033 (USD Billion)
  • Fig. 17 Polyenes market, 2021 - 2033 (USD Billion)
  • Fig. 18 Allylamines market, 2021 - 2033 (USD Billion)
  • Fig. 19 Others market, 2021 - 2033 (USD Billion)
  • Fig. 20 Indication market, 2021 - 2033 (USD Billion)
  • Fig. 21 Dermatophytosis market, 2021 - 2033 (USD Billion)
  • Fig. 22 Aspergillosis market, 2021 - 2033 (USD Billion)
  • Fig. 23 Candidiasis market, 2021 - 2033 (USD Billion)
  • Fig. 24 Others market, 2021 - 2033 (USD Billion)
  • Fig. 25 Dosage Form market, 2021 - 2033 (USD Billion)
  • Fig. 26 Oral Drugs market, 2021 - 2033 (USD Billion)
  • Fig. 27 Ointments market, 2021 - 2033 (USD Billion)
  • Fig. 28 Powders market, 2021 - 2033 (USD Billion)
  • Fig. 29 Others market, 2021 - 2033 (USD Billion)
  • Fig. 30 Distribution Channel market, 2021 - 2033 (USD Billion)
  • Fig. 31 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 32 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 33 Other pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 34 Antifungal drugs market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 43 Europe antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 48 France country dynamics
  • Fig. 49 France antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 60 Asia Pacific antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 63 China country dynamics
  • Fig. 64 China antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 65 India country dynamics
  • Fig. 66 India antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 73 Latin America antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 78 MEA antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis, 2024
  • Fig. 89 Strategic framework